Spondyloarthritis & psoriatic arthritis
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis
Main finding · Efficacy on disease activity, function, mobility (eg BASDAI)Result — go to the resultRange RR for ASAS20 1.91-3.10Authors' conclusion
Education, exercise and NSAIDs confirmed to be efficacious in axSpA. JAKi were proved efficacious in r-axSpA.
Study context
- Population
- Adult patients with r-axSpA and nr-axSpApublications included
- Participants
- 107 patients
- Comparison
- Non-pharmacological and non-biological pharmacological treatments vs active comparator or placebo
- Educationn = 8
- Exercisen = 20
- Targeted synthetic disease-modifying antirheumatic drugs (DMARDs)n = 6
- Conventional synthetic DMARDsn = 3
- Non-steroidal anti-inflammatory drugs (NSAIDs)n = 8
- Outcome
- Efficacy on disease activity, function, mobility (eg BASDAI)
Methodological detailsPICO format, 2016-2021, informing 2022 ASAS-EULAR recommendations
- PICO format
- 2016-2021
- Informing 2022 ASAS-EULAR recommendations
Main finding
As reported in the abstract
Range RR for ASAS20
1.91-3.10
- Education: Effect size (ES) on disease activity, function, mobility small to moderate (eg Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) ES)
- 0.06-0.59
- Exercise: moderate to high ES on these outcomes (eg BASDAI ES)
- 0.14-1.43
Original publication
Efficacy and safety of non-pharmacological and non-biological interventions: a systematic literature review informing the 2022 update of the ASAS/EULAR recommendations for the management of axial spondyloarthritis. Ann Rheum Dis. Published 19 October 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →